

## [Generative AI in Biology and Healthcare](https://www.youtube.com/watch?v=NHszJiL-9pM)

Welcome to GTC 2023.

I'm Kimberly Powell, the Vice President of Healthcare.

At every GTC, we invite innovators from across the globe, from across diverse backgrounds and every corner of the healthcare ecosystem to share new breakthroughs and applications that address the great challenges, needs, and opportunities in healthcare.

This GTC is just incredible.

Let me welcome and thank our speakers for joining us on this exciting AI journey to share the great impact AI is having on healthcare and patients' lives.

Medtronics' Austin Chang is talking on real-time AI applications.

Gretchen Jackson at Intuitive on actionable insights in surgery.

Mark Van Owen of PacBio is talking about how AI scales the throughput of genomics.

Parker Moss from Genomics England and Rosemary Sinclair-Docas at Oxford Nanopore are talking about the impact genomics is having on cancer care.

And Burkhard Rose from TU Munich on AI capturing the language of proteins.

Amgen's Christopher Langmead on the transformative AI platforms for biologics discovery.

And Kevin Yang at Microsoft Research on multimodal AI for protein engineering.

Bristol Myers Squibb, Kevin Brown talking about creating multimodal models for clinical trials.

And the team at Evozyne generating proteins with enhanced functionality.

It's here, the next wave of AI.

<br>

欢迎来到 GTC 2023。

我是医疗保健副总裁 Kimberly Powell。

在每一届 GTC 上，我们都会邀请来自全球各地、来自不同背景和医疗保健生态系统各个角落的创新者分享新的突破和应用，以应对医疗保健领域的巨大挑战、需求和机遇。

这个 GTC 真是不可思议。

让我欢迎并感谢我们的演讲者加入我们这一激动人心的 AI 之旅，分享 AI 对医疗保健和患者生活的巨大影响。

Medtronics 的 Austin Chang 正在谈论实时人工智能应用。

Intuitive 的 Gretchen Jackson 关于外科手术的可行见解。

PacBio 的 Mark Van Owen 正在谈论人工智能如何扩展基因组学的通量。

Genomics England 的 Parker Moss 和 Oxford Nanopore 的 Rosemary Sinclair-Docas 正在谈论基因组学对癌症治疗的影响。

来自 TU Munich 的 Burkhard Rose 在 AI 上捕捉了蛋白质的语言。

Amgen 的 Christopher Langmead 谈用于生物制剂发现的变革性 AI 平台。

微软研究院的 Kevin Yang 研究了用于蛋白质工程的多模式 AI。

Bristol Myers Squibb 和 Kevin Brown 谈论为临床试验创建多模态模型。

Evozyne 的团队生成功能增强的蛋白质。

下一波 AI 就在这里。

<br>

Generative AI has become a human co-creation engine.

Chat GPT has an uncanny ability to use and generate language.

It can summarize, answer questions, write in any form you ask.

It can write code, it can write an email, or even generate a table.

And Dali helped Cosmo Magazine design this stunning AI cover with an insanely complicated prompt.

A wide angle shot from below of a female astronaut with an athletic female body walking with swagger toward camera on Mars in an infinite universe in synthwave digital art.

And AlphaFold achieving experimental accuracy using generative AI to predict 3D structures of proteins.

Not just a breakthrough in a 60-year-old problem, but a seminal example and inspiration to biology and the computational chemistry field that AI can learn meaning in biology and generate ideas faster for scientists.

NVIDIA Clara is inspired by this work.

We set our charter to bring the most advanced computing approaches to the healthcare industry.

NVIDIA Clara is a suite of computing platforms, software, and services that now serves the breadth of healthcare applications, from imaging and instruments to genomics and drug discovery.

Generative AI has a broad utility in healthcare, and we are building software and services to accelerate its application.

R&D groups from large pharma, startups, academia need a streamlined way to get access to NVIDIA AI and Clara.

With our announcement today to offer NVIDIA DGX Cloud through partnerships with cloud service providers, Microsoft Azure, Google GCP, and Oracle OCI, we can now bring NVIDIA Clara to the healthcare industry with incredible speed and scale.

Increasing the reach of NVIDIA Clara is our incredible partner ecosystem.

Clara now has hundreds of partners ranging from the edge to cloud solutions.

<br>

生成式 AI 已成为人类共同创造的引擎。

Chat GPT 具有不可思议的使用和生成语言的能力。

它可以总结，回答问题，以你要求的任何形式写作。

它可以编写代码，可以编写电子邮件，甚至可以生成表格。

Dali 帮助 Cosmo Magazine 设计了这个令人惊叹的 AI 封面，提示极其复杂。

在 synthwave 数字艺术的无限宇宙中，从下方拍摄的一位女宇航员的广角镜头，她的运动女性身体昂首阔步地走向火星上的相机。

AlphaFold 使用生成 AI 来预测蛋白质的 3D 结构，从而实现了实验准确性。

这不仅是一个 60 年老问题的突破，而且是生物学和计算化学领域的一个开创性例子和灵感，即 AI 可以学习生物学中的意义并为科学家更快地产生想法。

NVIDIA Clara 的灵感来自于这项工作。

我们制定了章程，将最先进的计算方法引入医疗保健行业。

NVIDIA Clara 是一套计算平台、软件和服务，现在服务于广泛的医疗保健应用，从成像和仪器到基因组学和药物发现。

生成式 AI 在医疗保健领域具有广泛的用途，我们正在构建软件和服务以加速其应用。

来自大型制药公司、初创公司和学术界的研发团队需要一种简化的方式来访问 NVIDIA AI 和 Clara。

随着我们今天宣布通过与云服务提供商、Microsoft Azure、Google GCP 和 Oracle OCI 的合作伙伴关系提供 NVIDIA DGX Cloud，我们现在可以以惊人的速度和规模将 NVIDIA Clara 引入医疗保健行业。

扩大 NVIDIA Clara 的影响力是我们令人难以置信的合作伙伴生态系统。

Clara 现在拥有数百个合作伙伴，从边缘到云解决方案。

<br>

Genomics cloud and drug discovery platforms integrate NVIDIA Clara to accelerate scientific discovery.

Ecosystem integrators and service providers accelerate and customize NVIDIA Clara for healthcare enterprises.

Embedded edge solutions provide building and certifying NVIDIA Clara computing platforms for medical devices and life sciences instruments.

And machine learning platforms integrate NVIDIA Clara to manage the end-to-end life cycle of machine learning models.

Starting with AI for imaging, 90% of healthcare data is imaging.

We need an industry standard for building and deploying AI.

Muni is our suite of tools that tackles the entire AI life cycle.

We call it the AI factory.

Powerful tools that use AI to do the expensive data labeling through active learning and AI assistance.

And when there isn't sufficient data, we use generative AI for synthetic data generation.

Or when there's a lot of data, but it isn't labeled, self-supervised learning can train large transformer models that can be fine-tuned for downstream tasks.

And when data is decentralized, federated learning enables local training and sharing of privacy-preserving model updates.

And finally, packages up models in a standard format to be deployed across the Muni ecosystem.

Muni is integrated into cloud services like Amazon SageMaker, Google Medical Imaging Suite, and Oracle Cloud.

MLOps flywheel, weights, and biases make it easy to reproduce and standardize model development.

And solution delivery partners Deloitte, Quantify, and Kitware are helping set up AI factories for hospitals, pharmaceutical companies, and medical device makers.

It's an honor to be able to celebrate the amazing milestone of 1 million downloads from Muni at GTC 2023.

Just three years after the announcement of Project Muni, and with the incredible contributions from founding members, advisory board members, and developers, Muni has reached 1 million downloads.

A great congratulations to you all, and I look forward to millions more.

Don't miss Muni at GTC.

<br>

基因组学云和药物发现平台集成了 NVIDIA Clara 以加速科学发现。

生态系统集成商和服务提供商为医疗保健企业加速和定制 NVIDIA Clara。

嵌入式边缘解决方案为医疗设备和生命科学仪器提供构建和认证 NVIDIA Clara 计算平台。

机器学习平台集成了 NVIDIA Clara 来管理机器学习模型的端到端生命周期。

从用于影像的 AI 开始，90% 的医疗保健数据都是影像。

我们需要一个用于构建和部署 AI 的行业标准。

Muni 是我们处理整个 AI 生命周期的工具套件。

我们称之为人工智能工厂。

强大的工具，使用 AI 通过主动学习和 AI 协助进行昂贵的数据标记。

当没有足够的数据时，我们使用生成式 AI 来生成合成数据。

或者当有大量数据但未标记时，自监督学习可以训练大型 transformer 模型，这些模型可以针对下游任务进行微调。

当数据分散时，联邦学习可以进行本地培训和共享隐私保护模型更新。

最后，以标准格式打包模型，以便在 Muni 生态系统中部署。

Muni 已集成到 Amazon SageMaker、Google Medical Imaging Suite 和 Oracle Cloud 等云服务中。

MLOps 飞轮、重量和偏置使模型开发的重现和标准化变得容易。

解决方案交付合作伙伴 Deloitte、Quantify 和 Kitware 正在帮助为医院、制药公司和医疗设备制造商建立人工智能工厂。

很荣幸能够在 GTC 2023 上庆祝 Muni 达到 100 万次下载的惊人里程碑。

Project Muni 宣布仅三年后，在创始成员、顾问委员会成员和开发人员的巨大贡献下，Muni 的下载量已达到 100 万次。

非常祝贺你们所有人，我期待着更多的人。

不要错过 GTC 的 Muni。

<br>

The schedule is packed with hands-on training, workshops, and technical talks.

Muni gives developers a jumpstart with the Model Zoo, almost two dozen pre-trained models, like the Heart Segmentation Model from King's College and the Breast Density Calculation from Mayo Clinic.

These models are quite advanced.

Let's check out the Whole Brain Segmentation from Vanderbilt University.

It's a transformer model capable of segmenting 133 structures in the brain.

And each model is like this, where the model descriptions provide all the reference papers, the model architecture overview, data and training scripts, so developers can reproduce and build on existing research.

Let's take a closer look at some of the new generative AI models coming to Muni.

Muni, a framework for building and deploying medical AI, is also advancing generative AI with methods to create large synthetic data sets for training generalizable AI models that can learn from evolving patient data while preserving patient privacy.

The Latent Diffusion Model is a breakthrough in generative AI for medical imaging and is being developed by King's College London, co-founders of Muni.

This model can generate synthetic medical images of the human anatomy, including high-resolution brain images.

It was trained on the UK Biobank dataset and NVIDIA DGX Cloud in just one week, enabling researchers to control global and regional brain volumes and adjust for age, gender and disease.

Generative AI is already making an impact in clinical settings.

King's College London and University College London have developed a novel transformer-based outlier detector that aids in clinical evaluation of deployed segmentation models.

The results suggest that this approach can be used to ensure only expected and good quality data reaches downstream decision-making algorithms.

NVIDIA Mount Sinai and East River Imaging have collaborated to develop a new generative AI model for medical imaging known as RAD ImageGAN.

By utilizing the StyleGAN XL model and training it on the RAD ImageNet dataset, RAD ImageGAN has become the most diverse synthetic data generator for 2D medical imaging.

To access these models, visit the NVIDIA NGC catalog.

Ready to join the future of healthcare powered by generative AI?

Join the Muni community today.

Bristol Myers Squibb has been a world leader in cancer drug development for decades.

Clinical trials are a costly $500 billion per year and where 90% of drug candidates fail.

BMS has decades of clinical trial data and millions of CT scans, and it's using Muni to build large foundation models to improve their clinical trial outcomes.

Using self-supervised learning features of Muni, BMS created a semantic segmentation foundation model that detects, classifies and measures the patient data for a more consistent and accurate response assessment.

As you can see, imaging is the foundational tool in healthcare, used in every stage from screening, diagnosis to treatment.

2D imaging for annual screening and early detection, advanced 3D for quantitative image analysis and 4D that captures the motion and the function.

And now we're entering the fifth dimension, multiple real-time sensors that enables the medical devices to automatically perform tasks.

As the sensor technology and the fusion of sensors technology becomes more complex, new real-time computing platforms and AI applications will be required to do a myriad of tasks, starting with detecting, classifying and segmenting, moving to much more complex sensor fusion tasks like registering, mapping, tracking and navigating.

<br>

日程安排包括实践培训、研讨会和技术讲座。

Muni 为开发人员提供了 Model Zoo 的快速启动，几乎有两打预训练模型，例如国王学院的心脏分割模型和梅奥诊所的乳房密度计算。

这些模型相当先进。

让我们看看范德比尔特大学的全脑分割。

这是一个能够分割大脑中 133 个结构的 transformer 模型。

每个模型都是这样，其中模型描述提供了所有参考论文、模型架构概述、数据和训练脚本，因此开发人员可以在现有研究的基础上进行复制和构建。

让我们仔细看看 Muni 中的一些新的生成式 AI 模型。

Muni 是一个用于构建和部署医疗 AI 的框架，它还通过创建大型合成数据集的方法来推进生成 AI，以训练通用 AI 模型，这些模型可以从不断变化的患者数据中学习，同时保护患者隐私。

潜在扩散模型是医学成像生成人工智能领域的一项突破，由 Muni 的联合创始人伦敦国王学院开发。

该模型可以生成人体解剖学的合成医学图像，包括高分辨率脑图像。

它在英国生物银行数据集和 NVIDIA DGX Cloud 上仅用了一周时间就接受了培训，使研究人员能够控制全球和区域脑容量并针对年龄、性别和疾病进行调整。

生成式人工智能已经在临床环境中产生影响。

伦敦国王学院和伦敦大学学院开发了一种新型的基于 transformer 的异常值检测器，有助于对已部署的分割模型进行临床评估。

结果表明，这种方法可用于确保只有预期的和高质量的数据才能到达下游决策算法。

NVIDIA Mount Sinai 和 East River Imaging 合作开发了一种新的医学成像生成 AI 模型，称为 RAD ImageGAN。

通过利用 StyleGAN XL 模型并在 RAD ImageNet 数据集上对其进行训练，RAD ImageGAN 已成为用于 2D 医学成像的最多样化的合成数据生成器。

要访问这些模型，请访问 NVIDIA NGC 目录。

准备好加入由生成 AI 驱动的医疗保健的未来了吗？

立即加入 Muni 社区。

几十年来，Bristol Myers Squibb 一直是抗癌药物开发领域的世界领导者。

临床试验每年耗资 5000 亿美元，90% 的候选药物都失败了。

BMS 拥有数十年的临床试验数据和数百万次 CT 扫描，它正在使用 Muni 构建大型基础模型以改善其临床试验结果。

BMS 使用 Muni 的自我监督学习功能，创建了一个语义分割基础模型，用于检测、分类和测量患者数据，以实现更一致和准确的反应评估。

如您所见，成像是医疗保健的基础工具，用于从筛查、诊断到治疗的每个阶段。

用于年度筛查和早期检测的 2D 成像、用于定量图像分析的高级 3D 以及用于捕捉运动和功能的 4D。

现在我们正在进入第五维度，多个实时传感器使医疗设备能够自动执行任务。

随着传感器技术和传感器技术的融合变得越来越复杂，将需要新的实时计算平台和 AI 应用程序来执行大量任务，从检测、分类和分割开始，转向更复杂的传感器融合任务，例如 注册、映射、跟踪和导航。

<br>

This is why NVIDIA invented HoloScan, a real-time AI sensor platform.

NVIDIA HoloScan brings together end-to-end solutions to build and deploy AI for medical devices.

It brings together everything from the device to the data center.

Using Muni and our Omniverse digital twin platform to create and simulate AI.

And NVIDIA HoloScan, a full stack, scalable platform for real-time processing of streaming sensor data.

HoloScan provides a complete edge computing platform with all-in-one hardware systems, operating systems and an SDK that is cloud-native to scale applications to the cloud.

The HoloScan platform gives the medical device industry a unified and common computing platform.

And it's software-defined to realize the software-as-a-service business model, saving huge amounts of hardware and platform software engineering, making more resources available to develop life-saving healthcare applications.

Over 70 leading medical device companies, startups and medical centers are developing new real-time applications on NVIDIA HoloScan.

HoloScan comes with a suite of reference applications and the platform is sensor agnostic. With the lowest latency pipeline from sensor to multiple sensors in, to the advanced AI processing and advanced visualization.

Announcing today, I am excited to share that you can now place orders for HoloScan IGX Orin Developer Kits from our global distribution network.

The IGX Orin Developer Kits are an all-in-one industrial computer consisting of a high-speed sensor input, ConnectX, NIC, an Orin system-on-a-chip and an RTX GPU, with all the safety and security features needed for industrial and medical designs.

You can reach out to Arrow, P&Y, Leadtech, EDOM, RYOYO, MACNICA to order HoloScan IGX Developer Kits and begin prototyping today.

For putting HoloScan in production, Edge AI appliances built with IGX Orin will be available in the second half of this year from our global OEM and ODM network.

All great offerings are being made available from AdvanTech, Dedicated Computing, Cosmo Intelligent Devices, Portwell, ProDrive, AdLink and more.

Today we are announcing a remarkable partnership with the world leader in medical devices, Medtronic, to build the AI platform for medical devices.

NVIDIA and Medtronic have been working together for many years on many of their innovative platforms, from robotic-assisted surgery, surgical navigation, and interoperative imaging systems.

I was able to have a chat with Jeff Martha, CEO of Medtronic, about the impact AI is already having and his strategic vision for AI going forward. 

Jeff, it's so good to see you.

It's a wonderful opportunity to have you join us at GTC, the AI conference.

Well, thanks Kimberly.

I'm really excited.

When you first talked to me about it in January, I was really excited to join. 

It feels like it's the Super Bowl for AI and I couldn't be more excited to be here and talk about the progress that we're making together.

Absolutely.

Medtronic is the global leader in medical devices that has served over 76 million patients across 70 health conditions.

You've created the ultimate condition to broaden the impact of AI in healthcare.

You mentioned the 76 million patients, so that's 76 million patients a year.

That's about two patients every second.

And I'm convinced AI is going to help us move upstream to less sick people, high-risk people, and we're going to take that number to go from that, call it 80 million a year to 800 million a year.

I think that's the power that we have in front of us.

That's incredible, Jeff.

<br>

这就是 NVIDIA 发明实时 AI 传感器平台 HoloScan 的原因。

NVIDIA HoloScan 汇集了端到端解决方案，为医疗设备构建和部署人工智能。

它汇集了从设备到数据中心的一切。

使用 Muni 和我们的 Omniverse 数字孪生平台创建和模拟 AI。

以及 NVIDIA HoloScan，一个用于实时处理流式传感器数据的全堆栈、可扩展平台。

HoloScan 提供了一个完整的边缘计算平台，具有一体化硬件系统、操作系统和云原生 SDK，可将应用程序扩展到云端。

HoloScan平台为医疗器械行业提供了一个统一通用的计算平台。

并且它是软件定义的，以实现软件即服务的商业模式，节省大量的硬件和平台软件工程，使更多资源可用于开发救生医疗保健应用程序。

超过 70 家领先的医疗设备公司、初创公司和医疗中心正在 NVIDIA HoloScan 上开发新的实时应用程序。

HoloScan 附带一套参考应用程序，该平台与传感器无关。 具有从传感器到多个传感器的最低延迟管道，再到高级 AI 处理和高级可视化。

今天，我很高兴地宣布，您现在可以从我们的全球分销网络订购 HoloScan IGX Orin 开发人员套件。

IGX Orin 开发人员套件是一款一体化工业计算机，由高速传感器输入、ConnectX、NIC、Orin 片上系统和 RTX GPU 组成，具有 工业和医疗设计。

您可以联系 Arrow、P&Y、Leadtech、EDOM、RYOYO、MACNICA 订购 HoloScan IGX 开发套件并立即开始原型设计。

为了将 HoloScan 投入生产，使用 IGX Orin 构建的 Edge AI 设备将于今年下半年通过我们的全球 OEM 和 ODM 网络提供。

AdvanTech、Dedicated Computing、Cosmo Intelligent Devices、Portwell、ProDrive、AdLink 等公司提供所有优质产品。

今天，我们宣布与医疗设备领域的全球领导者美敦力 (Medtronic) 建立非凡的合作伙伴关系，以构建医疗设备的 AI 平台。

NVIDIA 和 Medtronic 多年来一直在他们的许多创新平台上合作，从机器人辅助手术、手术导航和互操作成像系统。

我能够与美敦力 (Medtronic) 首席执行官杰夫玛莎 (Jeff Martha) 聊聊人工智能已经产生的影响以及他对人工智能未来的战略愿景。

杰夫，很高兴见到你。

邀请您参加人工智能会议 GTC，这是一个绝佳的机会。

好吧，谢谢金佰利。

我很激动。

当你在一月份第一次和我谈起这件事时，我真的很高兴能加入。

感觉就像是 AI 的超级碗，我非常兴奋能来到这里谈论我们共同取得的进步。

绝对地。

美敦力 (Medtronic) 是医疗设备领域的全球领导者，已为 70 种健康状况下超过 7600 万名患者提供服务。

您已经为扩大 AI 在医疗保健领域的影响创造了最终条件。

你提到了 7600 万患者，所以每年有 7600 万患者。

每秒大约有两个病人。

而且我相信人工智能将帮助我们向上游转移到患病较少的人、高风险人群，我们将从这个数字开始，将其称为每年 8000 万到每年 8 亿。

我认为这就是我们面前的力量。

太不可思议了，杰夫。

<br>

Two patients a second, and your vision is to take that to 20 patients a second? 

Can you tell us more about how we make this vision possible and the role AI plays in medical devices and the applications in patient care?

I talk to physicians every day and look, they don't want more data.

They want insights.

They want insights that can lead to action.

And so, you know, for us to do this at scale and speed to meaningfully impact society, we need AI.

It's that simple.

And I believe, you know, we've only just scratched the surface of what's possible.

Jeff, you make two really critical points.

AI is a technology to deliver insights, insights to clinicians that benefit patients.

I think your other point you made is, you know, we're just at the beginning of this journey.

AI, just like human intelligence, is a journey of continuous learning and evolution.

So can you share with us any specific use cases, for example, in early cancer screening or surgery, where AI has already made a significant impact within Medtronic and for the health care providers?

Sure.

You know, I'm happy to share that we're already seeing a number of benefits of AI in a number of areas.

So, one, our GI Genius Intelligent Endoscopy Module is the first computer-aided detection system to use AI to identify polyps during a colonoscopy.

So GI Genius scans every visual frame of the entire procedure in real time and then alerts physicians to the presence of lesions, including small, flat polyps that can be easily, can easily go undetected by the human eye, especially after a long day of doing colonoscopies.

These things, physicians can miss these.

And we recently published the results of our largest trial to date, demonstrating just how using GI Genius can reduce the miss rate of polyps by up to 50% compared to a human-only colonoscopy.

And that's just huge.

The potential of AI is essentially limitless.

And considering colon cancer, as you said, it's the second most common cancer cause of death in the United States.

But it's also the most curable if caught early.

And the AI applications provided by GI Genius platform are helping.

As you said, the clinicians are seeing and catching 50% more cases.

This is absolutely life-changing.

Jeff, this is exactly what inspired us to build the NVIDIA HoloScan platform.

How do you see HoloScan providing value to Medtronic and, in turn, bringing support to the physicians and the care that they provide?

Where I think NVIDIA's technologies really play a major role is providing a comprehensive experience to developers and medical device makers who want to create AI-based medical applications.

So any new product development is labor-intensive and very time-consuming.

So the integration of Medtronic's GI Genius Intelligent Endoscopy Module with NVIDIA's latest technologies, like HoloScan and IGX, has the potential to significantly accelerate

AI innovation for healthcare.

And it will allow thousands of developers worldwide to get involved in the future of medical AI and to help benefit millions of patients.

So our work together here is going to increase the scale and the speed of medical AI innovation and help shape the future of healthcare.

It's a challenge, and really more of a challenge, it's an opportunity that I'm proud for us to be a part of and a lead role with you.

We feel the same way, and we're excited to partner with you and the Medtronic team to build this AI platform for medical devices.

It's very exciting to hear that GI Genius, based on NVIDIA HoloScan, is going to start bringing many more applications to the bedside for the clinicians and the patients, even as early as the end of the year.

We have an incredible future ahead of us.

Thank you so much for telling the world about it today.

Sounds good.

Thank you for having me again.

<br>

每秒两个病人，你的愿景是每秒处理 20 个病人？

你能告诉我们更多关于我们如何使这一愿景成为可能以及人工智能在医疗设备和患者护理应用中扮演的角色吗？

我每天都和医生交谈，他们不想要更多数据。

他们想要洞察力。

他们想要能够促成行动的见解。

所以，你知道，为了让我们大规模和快速地做到这一点以对社会产生有意义的影响，我们需要人工智能。

就这么简单。

我相信，你知道，我们只是触及了可能性的表面。

杰夫，你提出了两个非常关键的观点。

人工智能是一种技术，可以为临床医生提供有益于患者的见解和见解。

我认为你提出的另一点是，你知道，我们才刚刚开始这个旅程。

人工智能就像人类智能一样，是一个不断学习和进化的旅程。

那么，您能否与我们分享任何具体的用例，例如，在早期癌症筛查或手术中，人工智能已经在美敦力内部和医疗保健提供者中产生了重大影响？

当然。

你知道，我很高兴与大家分享，我们已经在许多领域看到了人工智能的诸多好处。

因此，首先，我们的 GI Genius 智能内窥镜模块是第一个在结肠镜检查期间使用 AI 识别息肉的计算机辅助检测系统。

因此 GI Genius 实时扫描整个过程的每个视觉帧，然后提醒医生注意病变的存在，包括小而扁平的息肉，这些息肉很容易被人眼检测不到，尤其是在经过一整天的工作后 结肠镜检查。

这些东西，医生可能会错过这些。

我们最近发布了迄今为止最大规模的试验结果，展示了与仅由人类进行的结肠镜检查相比，使用 GI Genius 可以将息肉漏检率降低多达 50%。

那是巨大的。

人工智能的潜力本质上是无限的。

考虑到结肠癌，正如您所说，它是美国第二大最常见的癌症死因。

但如果及早发现，它也是最可治愈的。

而GI Genius平台提供的人工智能应用正在提供帮助。

正如您所说，临床医生发现并发现的病例增加了 50%。

这绝对是改变生活的。

Jeff，正是这启发了我们构建 NVIDIA HoloScan 平台。

您如何看待 HoloScan 为美敦力提供价值，进而为医生和他们提供的护理提供支持？

我认为 NVIDIA 的技术真正发挥重要作用的地方是为想要创建基于 AI 的医疗应用程序的开发人员和医疗设备制造商提供全面的体验。

因此，任何新产品开发都是劳动密集型且非常耗时的。

因此，将 Medtronic 的 GI Genius 智能内窥镜模块与 NVIDIA 的最新技术（如 HoloScan 和 IGX）相结合，有可能显着加速

人工智能医疗保健创新。

它将使全球数以千计的开发人员能够参与医疗人工智能的未来，并帮助数百万患者受益。

因此，我们在这里的合作将扩大医疗 AI 创新的规模和速度，并帮助塑造医疗保健的未来。

这是一个挑战，实际上更是一个挑战，这是一个机会，我很自豪我们能成为你们的一员并与你们一起发挥领导作用。

我们也有同感，我们很高兴与您和美敦力团队合作，为医疗设备构建这个 AI 平台。

听到基于 NVIDIA HoloScan 的 GI Genius 将开始为临床医生和患者带来更多床边应用程序，甚至最早在今年年底，我感到非常兴奋。

我们有一个不可思议的未来。

非常感谢你今天向全世界讲述这件事。

听起来不错。

谢谢你再次邀请我。

<br>

We couldn't be more excited to be working with Jeff and his team. 

And today, we're also announcing Medtronic is designing their GI Genius AI-assisted colonoscopy system with NVIDIA HoloScan and IGX to support physicians with real-time AI-enhanced imaging, shipping at the end of the year.

GI Genius has been designed to host a suite of AI algorithms, like the Intelligent Endoscopy Module, the first FDA-accleared AI-assisted colonoscopy tool.

It helps physicians detect polyps that can lead to colorectal cancer.

Working with the GI business at Medtronic and partner Cosmo, we are also helping enable third-party developers to train and validate AI models for the GI Genius platform, accelerating important applications to get to market.

Another field that is continuously pioneering ways to leverage AI is genomics.

Last year was an incredible year.

NVIDIA worked across the entire ecosystem to make NVIDIA Parabricks accessible in all public and genomics cloud platforms.

New genomics sequencing platform introductions using AI to increase instrument throughput and reduce the cost of sequencing to just hundreds of dollars.

And achieving the Guinness World Record time of five hours for diagnostic sequencing technique. 

There are two monumental achievements bringing genomic sequencing closer to becoming the standard of care.

And for the first time, the completion of the whole human genome was accomplished by the Telomere-to-Telomere Consortium, introducing another 200 million genomic bases to the genome.

Long read sequencing and the platforms invented by Oxford Nanopore and PacBio are the core to this achievement, along with many more discoveries in transcriptomics and epigenomics toward long read sequencing, nature's method of the year in 2022.

Genomic sequencing platforms far outpace Moore's law and throughput of the instruments is what drives the cost down.

NVIDIA Parabricks is accelerating every stage of the genomics analysis pipeline, driving up throughput and accuracy while driving down cost.

Today, instruments want to become more turnkey so they can live on the benchtop in a hospital for clinical use or in a lab at a drug discovery startup.

Using AI and accelerated computing, we are bringing compute and the workflow to the instrument as well as making it available on every cloud.

With our next release, Parabricks 4.1, whole genome sequencing analysis will be further accelerated from 21 minutes to just 16 minutes.

Also coming to Parabricks 4.1, we are introducing the end-to-end PacBio accelerated analysis pipeline, inclusive of accelerated Minimap2 alignment and a fine-tuned deep variant model.

This will be made available in NVIDIA NGC Catalog and in NextFlow and Whittle workflows on the Terra cloud platform in Q2.

Another new introduction in Parabricks 4.1 is a new deep variant retraining tool to enable instrument vendors, researchers, and genomic centers to customize and fine-tune deep variant models to new and evolving chemistry and sequencing methods for more accurate variant calling.

The framework will also be made available in NVIDIA NGC Catalog in Q2.

Some incredible new platforms are coming to the market, and we are excited to be working with such innovative companies like BioNano, who is transforming the way we see genomics through optical genome mapping.

BioNano's Sapphire system is breaking new barriers to the resolution at which we can detect structural variants.

Structural variants can disrupt the normal function of a gene and contribute to a broad range of genetic diseases and cancer.

We are working together to build on-instrument and cloud analysis workflows that tackle over 96 cancer workflows and integrate into BioNano's NxClinic software for accelerated interpretation and reporting.

And another occurring in the field that is being referred to as the fourth generation in genomics, spatial genomics is the study of single-cell genomics in both 2D and 3D organization within a tissue sample.

Giving new understanding of how cells interact and the genes they express has broad application to basic biology research, clinical diagnostics, and drug discovery.

The nanostring's new COSMIC system is capable of taking a tissue of a million cells and visualizing a thousand different gene expressions in each of those cells in its X, Y, and Z coordinates.

That number is growing to 6,000 different gene expressions by the end of the year, producing three to six terabytes of data per mole or tumor sampled.

<br>

能与 Jeff 和他的团队一起工作，我们感到无比兴奋。

今天，我们还宣布美敦力 (Medtronic) 正在使用 NVIDIA HoloScan 和 IGX 设计他们的 GI Genius AI 辅助结肠镜检查系统，以支持具有实时 AI 增强成像的医生，该系统将于今年年底发货。

GI Genius 旨在承载一套 AI 算法，例如智能内窥镜模块，这是 FDA 批准的第一个 AI 辅助结肠镜检查工具。

它可以帮助医生检测可能导致结直肠癌的息肉。

通过与美敦力 (Medtronic) 的 GI 业务和合作伙伴 Cosmo 合作，我们还帮助第三方开发人员为 GI Genius 平台训练和验证 AI 模型，加速重要应用程序进入市场。

另一个不断开拓利用 AI 的方法的领域是基因组学。

去年是不可思议的一年。

NVIDIA 在整个生态系统中开展工作，使 NVIDIA Parabricks 可在所有公共和基因组学云平台上访问。

引入新的基因组学测序平台，使用 AI 提高仪器通量并将测序成本降低至仅数百美元。

并创造了诊断测序技术五小时的吉尼斯世界纪录。

有两项巨大的成就使基因组测序更接近于成为护理标准。

并且第一次，整个人类基因组的完成是由端粒到端粒联盟完成的，向基因组引入了另外 2 亿个基因组碱基。

长读长测序和 Oxford Nanopore 和 PacBio 发明的平台是这一成就的核心，此外还有转录组学和表观基因组学方面的更多发现，长读长测序是自然界 2022 年的年度方法。

基因组测序平台远远超过摩尔定律，仪器的吞吐量是推动成本下降的原因。

NVIDIA Parabricks 正在加速基因组学分析管道的每个阶段，提高吞吐量和准确性，同时降低成本。

如今，仪器希望变得更加交钥匙，以便它们可以在医院的工作台上用于临床或在药物发现初创公司的实验室中使用。

使用人工智能和加速计算，我们将计算和工作流程引入仪器，并使其在每个云上都可用。

在我们的下一个版本 Parabricks 4.1 中，全基因组测序分析将从 21 分钟进一步加速到仅 16 分钟。

在 Parabricks 4.1 中，我们还引入了端到端 PacBio 加速分析管道，包括加速 Minimap2 比对和微调的深度变异模型。

这将在第二季度的 NVIDIA NGC 目录以及 Terra 云平台上的 NextFlow 和 Whittle 工作流中提供。

Parabricks 4.1 中的另一个新介绍是一种新的深度变异再训练工具，使仪器供应商、研究人员和基因组中心能够定制和微调深度变异模型，以适应新的和不断发展的化学和测序方法，以实现更准确的变异识别。

该框架也将于第二季度在 NVIDIA NGC 目录中提供。

一些令人难以置信的新平台正在进入市场，我们很高兴能与像 BioNano 这样的创新公司合作，他们正在通过光学基因组作图改变我们看待基因组学的方式。

BioNano 的蓝宝石系统打破了我们检测结构变异分辨率的新障碍。

结构变异会破坏基因的正常功能，并导致广泛的遗传疾病和癌症。

我们正在共同努力构建仪器和云分析工作流程，以处理超过 96 种癌症工作流程，并将其集成到 BioNano 的 NxClinic 软件中以加速解释和报告。

该领域中出现的另一个被称为基因组学第四代的空间基因组学是研究组织样本中 2D 和 3D 组织中的单细胞基因组学。

对细胞如何相互作用及其表达的基因有了新的认识，可广泛应用于基础生物学研究、临床诊断和药物发现。

纳米线的新 COSMIC 系统能够获取一百万个细胞的组织，并在其 X、Y 和 Z 坐标中可视化每个细胞中的一千种不同基因表达。

到今年年底，这个数字将增长到 6,000 种不同的基因表达，每个痣或肿瘤样本产生三到六太字节的数据。

<br>

Nanostring built NVIDIA into the imaging platform to do a critical step of cell segmentation, identifying the cell boundaries.

And next, we're going to be working together on large AI models applied to these gigantic data sets.

Three critical paradigms are creating the watershed moment for biology. 

Digital biology.

We just covered some of the most innovative medical devices that are core to generating new biology data with new levels of resolution.

So we can use computational and mathematical methods to model biological systems, accelerate the discovery of new therapies, and improve our ability to predict and treat diseases.

At the same time, the drug discovery process, design, make, test, is being revolutionized by sensors and robotics to automate labs, and it's vastly increasing the amount of data available for analysis in biology and drug discovery.

And here we are, in the chat GPT moment, with an unprecedented new ability for generative

AI to learn relationships, reason, and predict things from large amounts of biology data.

And the research shows that generative AI is able to learn and represent biology, and it's transforming biology from science to engineering.

DeepMind's AlphaFold began the mission and won the method of the year in 2021 with a stunning achievement, using a large language model to achieve experimental accuracy for 3D structure prediction of proteins.

Fast following seminal research from Meta, RoastLab, BakerLab, BarzilayLab, and a thousand more papers in 2022.

DeepMind's collaborative research is broad sweeping across life sciences and drug discovery.

Like predicting new COVID variants with Argonne National Lab, don't miss Arvind Ramanathan's presentation this week.

Other great work includes generalizable DNA transformer with InstaDeep, and a functional protein generator with Evozyme, a protein ligand complex predictor with Caltech and Centose, and a molecule generator with AstraZeneca, and finally, a property controlled molecule generator.

Generative AI has broad applicability to the end-to-end pharmaceutical industry.

Generative AI in biology is innovating the early discovery process from target discovery to de novo design.

Generative AI in imaging is helping to discover new biomarkers and improve clinical trial design and outcomes.

And generative AI in language is finding new therapeutic targets and adverse events in health records and real-world data.

The pharmaceutical industry is approaching $2 trillion, yet we still have tens of thousands of diseases without cures.

With $250 billion spent in R&D, another $500 billion spent in clinical trials, the urgency to apply AI to reduce the 10 years and $2 billion to get a drug to market is imperative across the industry.

We have now created a streamlined way to give the industry access to NVIDIA AI and Clara.

With our announcement of NVIDIA DGX Cloud availability through partnerships with Microsoft Azure, Google GCP, and Oracle OCI.

Today, we are announcing NVIDIA BioNemo cloud services for generative AI and drug discovery.

BioNemo service is a suite of pre-trained and optimized open-source models that provide easy access for drug discovery workflows in 3D protein structure prediction, small molecule generation, property predictions, and molecular docking.

BioNemo provides optimized models and model hosting so that drug discovery teams can easily deploy and scale generative AI workloads.

Let's take a look at BioNemo in action.

Drug discovery is incredibly hard.

Bringing a new drug to market takes more than 10 years and has just a 10% success rate. 

Between the complexity of biology and the near infinite chemical and protein combinations, discovering drugs to help cure disease is a truly heroic endeavor.

Accelerating this process is mission critical for drug developers.

There are three key stages to drug discovery.

Discovering the biology that causes disease, designing new molecules, whether those are small molecules, proteins, or antibodies, and finally, screening how those molecules interact with each other.

Today, generative AI is transforming every step of the drug discovery process.

<br>

Nanostring 将 NVIDIA 内置到成像平台中，以执行细胞分割的关键步骤，识别细胞边界。

接下来，我们将合作开发应用于这些巨大数据集的大型 AI 模型。

三个关键范式正在创造生物学的分水岭时刻。

数字生物学。

我们刚刚介绍了一些最具创新性的医疗设备，这些设备是生成具有新分辨率水平的新生物学数据的核心。

因此，我们可以使用计算和数学方法对生物系统进行建模，加速新疗法的发现，并提高我们预测和治疗疾病的能力。

与此同时，传感器和机器人技术正在彻底改变药物发现过程、设计、制造、测试，以实现实验室自动化，并极大地增加了可用于生物学和药物发现分析的数据量。

在这里，在聊天 GPT 时刻，我们拥有前所未有的新生成能力

AI 从大量生物学数据中学习关系、推理和预测事物。

研究表明，生成式 AI 能够学习和表征生物学，它正在将生物学从科学转变为工程学。

DeepMind 的 AlphaFold 开始了使命，并以惊人的成绩赢得了 2021 年的年度方法，使用大型语言模型实现了蛋白质 3D 结构预测的实验准确性。

快速追踪来自 Meta、RoastLab、BakerLab、BarzilayLab 的开创性研究，以及 2022 年的一千多篇论文。

DeepMind 的合作研究广泛涉及生命科学和药物发现。

就像使用阿贡国家实验室预测新的 COVID 变体一样，不要错过 Arvind Ramanathan 本周的演讲。

其他伟大的工作包括 InstaDeep 的通用 DNA 转换器，Evozyme 的功能性蛋白质生成器，Caltech 和 Centose 的蛋白质配体复合物预测器，AstraZeneca 的分子生成器，最后是属性控制的分子生成器。

生成式人工智能对端到端制药行业具有广泛的适用性。

生物学中的生成式 AI 正在革新从目标发现到从头设计的早期发现过程。

成像中的生成式 AI 有助于发现新的生物标志物并改进临床试验设计和结果。

语言中的生成式 AI 正在健康记录和真实世界数据中寻找新的治疗目标和不良事件。

制药业接近 2 万亿美元，但我们仍有数以万计的疾病无法治愈。

2500 亿美元用于研发，另外 5000 亿美元用于临床试验，应用 AI 缩短 10 年时间的紧迫性以及 20 亿美元将药物推向市场的紧迫性在整个行业势在必行。

我们现在已经创建了一种简化的方式，让业界能够访问 NVIDIA AI 和 Clara。

通过与 Microsoft Azure、Google GCP 和 Oracle OCI 的合作，我们宣布了 NVIDIA DGX Cloud 的可用性。

今天，我们宣布推出用于生成人工智能和药物发现的 NVIDIA BioNemo 云服务。

BioNemo 服务是一套经过预训练和优化的开源模型，可轻松访问 3D 蛋白质结构预测、小分子生成、特性预测和分子对接中的药物发现工作流程。

BioNemo 提供优化的模型和模型托管，以便药物发现团队可以轻松部署和扩展生成式 AI 工作负载。

让我们来看看 BioNemo 的实际应用。

药物发现非常困难。

将一种新药推向市场需要 10 多年的时间，而且只有 10% 的成功率。

在生物学的复杂性和近乎无限的化学和蛋白质组合之间，发现有助于治愈疾病的药物是一项真正的英勇努力。

加速这一过程对药物开发人员来说至关重要。

药物发现分为三个关键阶段。

发现导致疾病的生物学机制，设计新分子，无论是小分子、蛋白质还是抗体，最后筛选这些分子如何相互作用。

如今，生成式人工智能正在改变药物发现过程的每一步。

<br>

NVIDIA BioNemo service provides state-of-the-art generative AI models for drug discovery.

It's available as a cloud service, providing instant and easy access to accelerated drug discovery workflows.

BioNemo includes models like AlphaFold, ESMFold, and OpenFold for 3D protein structure prediction, ProatGPT for protein generation, ESM1 and ESM2 for protein property prediction, MegaMoleBart and MoleFlow for molecule generation, and DiffDock for molecule docking.

Drug discovery teams can use the models through BioNemo's web interface or cloud APIs.

Here's an example of using NVIDIA BioNemo for drug discovery virtual screening.

Generative models can now read a protein's amino acid sequence and, in seconds, accurately predict the structure of a target protein.

They can also generate molecules with desirable ADME properties that optimize how a drug behaves in the body.

Generative models can even predict the 3D interactions of a protein and molecule, accelerating the discovery of optimal drug candidates.

With NVIDIA DGX Cloud, BioNemo also provides on-demand supercomputing infrastructure to further optimize and train models, saving teams valuable time and money so they can focus on discovering life-saving medicines.

The new AI drug discovery pipelines are here.

Sign up now for access to NVIDIA BioNemo service.

Many pharma and biotech companies want to build custom models that leverage their decades' worth of valuable proprietary data and their subject matter expertise into these models. 

BioNemo helps researchers create and fine-tune custom models with their proprietary data, with on-demand supercomputing infrastructure offered through NVIDIA DGX Cloud and BioNemo training service.

Let's take a look at how Amgen uses BioNemo services.

Amgen is a world leader in antibody discovery and development, with a long history of successful antibody drugs and antibody creation platforms.

Chris Langmead and the Digital Biologics Discovery team use BioNemo service to customize five property prediction models with their own proprietary antibody data, and then run BioNemo structure prediction models to generate proteins for further design consideration.

The team was able to reduce the time to develop these generative AM models from three months to four weeks, with a just-bring-your-data approach and let BioNemo training service take care of the infrastructure, the software, the pre-trained models, and optimization, and of course, our fantastic experts standing by for questions.

And the models we used for structure prediction were optimized to run five to a hundred times faster.

Don't miss Chris's full talk at GTC.

NVIDIA and Deloitte announced our partnership last GTC, and Deloitte has been a power user of BioNemo ever since.

The Molecular Modeling and Drug Discovery team at Deloitte has developed a new structural drug discovery pipeline called ProMap.

The pipeline takes advantage of the fact that BioNemo offers multiple structure prediction models, and their application can intelligently choose the right model for the right job.

Here's how ProMap works.

First, an intelligent proprietary upstream classifier chooses the best model according to the amino acid sequence.

It calls BioNemo service APIs and performs optimized structure prediction.

And then a downstream Deloitte in-house generative AI model refines the structure to predict the druggable regions shown in red.

This is a perfect example of how easy it is to innovate and build drug discovery applications with BioNemo cloud services.

NVIDIA BioNemo service for generative AI and drug discovery offers instantaneous, optimized, scalable services to quickly customize and deploy state-of-the-art biomolecular models.

<br>

NVIDIA BioNemo 服务为药物发现提供最先进的生成式 AI 模型。

它以云服务的形式提供，提供对加速药物发现工作流程的即时和轻松访问。

BioNemo 包括用于 3D 蛋白质结构预测的 AlphaFold、ESMFold 和 OpenFold 等模型，用于蛋白质生成的 ProatGPT，用于蛋白质特性预测的 ESM1 和 ESM2，用于分子生成的 MegaMoleBart 和 MoleFlow，以及用于分子对接的 DiffDock。

药物发现团队可以通过 BioNemo 的网络界面或云 API 使用这些模型。

下面是使用 NVIDIA BioNemo 进行药物发现虚拟筛选的示例。

生成模型现在可以读取蛋白质的氨基酸序列，并在几秒钟内准确预测目标蛋白质的结构。

它们还可以生成具有理想 ADME 特性的分子，从而优化药物在体内的表现。

生成模型甚至可以预测蛋白质和分子的 3D 相互作用，从而加速最佳候选药物的发现。

借助 NVIDIA DGX Cloud，BioNemo 还提供按需超级计算基础设施，以进一步优化和训练模型，为团队节省宝贵的时间和金钱，使他们能够专注于发现救生药物。

新的 AI 药物发现管道就在这里。

立即注册以访问 NVIDIA BioNemo 服务。

许多制药和生物技术公司希望构建自定义模型，将他们数十年来宝贵的专有数据及其主题专业知识利用到这些模型中。

BioNemo 通过 NVIDIA DGX Cloud 和 BioNemo 培训服务提供的按需超级计算基础设施，帮助研究人员使用他们的专有数据创建和微调自定义模型。

让我们来看看 Amgen 如何使用 BioNemo 服务。

Amgen 是抗体发现和开发领域的全球领导者，在成功开发抗体药物和抗体创建平台方面拥有悠久的历史。

Chris Langmead 和 Digital Biologics Discovery 团队使用 BioNemo 服务用他们自己专有的抗体数据定制了五个属性预测模型，然后运行 BioNemo 结构预测模型来生成蛋白质以供进一步设计考虑。

该团队能够将开发这些生成性 AM 模型的时间从三个月减少到四个星期，采用只带数据的方法，并让 BioNemo 培训服务负责基础设施、软件和预训练模型 和优化，当然还有我们出色的专家随时待命。

我们用于结构预测的模型经过优化，运行速度提高了五到一百倍。

不要错过 Chris 在 GTC 上的完整演讲。

NVIDIA 和 Deloitte 在上届 GTC 上宣布了我们的合作伙伴关系，从那时起 Deloitte 一直是 BioNemo 的超级用户。

德勤的分子建模和药物发现团队开发了一种名为 ProMap 的新结构药物发现管道。

该管道利用了 BioNemo 提供多种结构预测模型这一事实，它们的应用程序可以智能地为正确的工作选择正确的模型。

ProMap 的工作原理如下。

首先，智能专有上游分类器根据氨基酸序列选择最佳模型。

它调用 BioNemo 服务 API 并执行优化的结构预测。

然后下游德勤内部生成人工智能模型改进结构以预测以红色显示的可药物化区域。

这是一个完美的例子，说明使用 BioNemo 云服务创新和构建药物发现应用程序是多么容易。

用于生成人工智能和药物发现的 NVIDIA BioNemo 服务提供即时、优化、可扩展的服务，以快速定制和部署最先进的生物分子模型。

<br>

The interest and adoption from the industry is incredible.

Broad sweeping from large pharma, tech bio, drug discovery SaaS platforms, and global system integrators, BioNemo will continue to work with the industry to develop and include models to address the end-to-end drug discovery process and provide customization on proprietary data to increase the pace of innovation and discovery.

BioNemo is in early access, and we will plan general availability second half of this year.

Japan is the third largest pharmaceutical industry in the world, making it a unique destination for drug discovery innovation.

Today, Mitsui and NVIDIA are announcing TokyoOne, the first pharmaceutical supercomputer to accelerate drug discovery with generative AI in Japan.

Japan is home to several leading drug discovery companies, including Astellas Pharma, Daiichi Sankyo, Ono Pharmaceutical, and Zurica, Mitsui's own AI drug discovery platform.

TokyoOne will be an innovation hub that enables the pharma industry to transform the landscape, providing 16 NVIDIA DGX-H100 nodes, supporting molecular dynamics simulations, large language model training, quantum chemistry, and generative AI.

TokyoOne will be live in the second half of 2023.

NVIDIA Clara, our suite of AI platforms, software, and services, brings the most advanced computing approaches to the healthcare and life sciences industry.

Medical devices of all kinds are accelerating and becoming software-defined with AI.

We are delighted to be partnering with Medtronic to build the medical AI platform for medical devices, and look forward to HoloScan shipping in their GI Genius AI-assisted colonoscopy system later this year.

Imaging and genomics have ignited the digital biology revolution, and new modalities and automation are generating datasets too complex for humans alone to interpret.

Generative AI has begun writing the next chapter of AI, where every industry will be able to access powerful, co-creative abilities that generate new ideas and discoveries.

The healthcare industry needs to access NVIDIA AI and Clara platforms faster and easier.

NVIDIA DGX Cloud, through partnerships with Microsoft Azure, Google GCP, and Oracle OCI, gives instant access to DGX AI supercomputers and NVIDIA software and services right from your browser.

NVIDIA BioNemo service helps researchers and drug discovery teams create, fine-tune, and serve optimized and custom biomolecular models with their proprietary data.

Amgen, a world leader in antibody therapies, is an early adopter of NVIDIA DGX Cloud and BioNemo to accelerate biologics discovery with generative AI and their own data.

And Japan, the third largest pharmaceutical market in the world, will be turbocharged to accelerate drug discovery with Mitsui's TokyoOne NVIDIA DGX supercomputer, an innovation hub for the industry.

Welcome to the next chapter of AI.

Have a great GTC!

Thank you for watching.

For more information, please visit www.ncbi.nlm.nih.gov.

<br>

业界的兴趣和采用令人难以置信。

BioNemo 广泛涉足大型制药、科技生物、药物发现 SaaS 平台和全球系统集成商，将继续与业界合作开发和纳入模型，以解决端到端的药物发现过程，并提供专有数据的定制 加快创新和发现的步伐。

BioNemo 处于抢先体验阶段，我们计划在今年下半年全面上市。

日本是世界第三大制药业，使其成为药物发现创新的独特目的地。

今天，三井物产和 NVIDIA 宣布推出 TokyoOne，这是日本第一台利用生成式 AI 加速药物发现的制药超级计算机。

日本是几家领先的药物发现公司的所在地，包括安斯泰来制药、第一三共制药、小野制药和三井自己的人工智能药物发现平台 Zurica。

TokyoOne 将成为一个创新中心，使制药行业能够改变格局，提供 16 个 NVIDIA DGX-H100 节点，支持分子动力学模拟、大型语言模型训练、量子化学和生成 AI。

TokyoOne 将于 2023 年下半年上线。

NVIDIA Clara 是我们的 AI 平台、软件和服务套件，可为医疗保健和生命科学行业带来最先进的计算方法。

各种医疗设备都在加速发展，并通过人工智能实现软件定义。

我们很高兴与美敦力合作，为医疗设备构建医疗人工智能平台，并期待今年晚些时候在他们的 GI Genius 人工智能辅助结肠镜检查系统中推出 HoloScan。

成像和基因组学点燃了数字生物学革命，新的模式和自动化正在生成过于复杂的数据集，单靠人类无法解释。

生成式 AI 已经开始谱写 AI 的新篇章，每个行业都将能够获得强大的共同创造能力，从而产生新的想法和发现。

医疗保健行业需要更快、更轻松地访问 NVIDIA AI 和 Clara 平台。

NVIDIA DGX Cloud 通过与 Microsoft Azure、Google GCP 和 Oracle OCI 的合作，让您可以直接从浏览器即时访问 DGX AI 超级计算机和 NVIDIA 软件和服务。

NVIDIA BioNemo 服务可帮助研究人员和药物发现团队使用其专有数据创建、微调和提供优化和定制的生物分子模型。

Amgen 是抗体疗法领域的全球领导者，它是 NVIDIA DGX Cloud 和 BioNemo 的早期采用者，通过生成 AI 和他们自己的数据来加速生物制剂的发现。

而作为世界第三大制药市场的日本，将借助三井的 TokyoOne NVIDIA DGX 超级计算机（该行业的创新中心）加速药物研发。

欢迎来到 AI 的下一章。

有一个伟大的 GTC！

感谢您的收看。

如需更多信息，请访问 www.ncbi.nlm.nih.gov。
